On the CHOPping block? Rethinking initial therapy for PMBCL
Authors:
- 4 December 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 146 (23) , 2732-2734
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trialBlood, 2025
- Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphomaBlood Advances, 2025
- Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial ResultsJournal of Clinical Oncology, 2024
- Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patientsHaematologica, 2023
- Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialHemaSphere, 2023
- Circulating Tumor DNA in Lymphoma: Principles and Future DirectionsBlood Cancer Discovery, 2022
- How I treat primary mediastinal B-cell lymphomaBlood, 2018
- End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision makingHaematologica, 2018
- Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R‐CHOP 14 versus 21 trialBritish Journal of Haematology, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016